Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Early Breast Cancer × pyrotinib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 57 HER2-positive Breast Cancer 15 HER2 Positive Metastatic Breast Cancer 3 HER2 Positive Breast Cancer 3 Breast Diseases 3 Brain Neoplasms 3 Advanced Breast Cancer 3 HER2-positive Metastatic Breast Cancer 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Triple Negative Breast Neoplasms 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Metastatic Breast Cancer in the Brain 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2+ Early or Locally Advanced Breast Cancer 1 HER2+ Breast Cancer 1 Estrogen Receptor-positive Breast Cancer 1 Breast Neoplasm Female 1 Breast Cancer Metastatic 1

Interventions

Trastuzumab 4 pertuzumab 3 Docetaxel 3 Carboplatin 3 pyrotinib 1 Taxes 1 Surgical Procedures, Operative 1 Doxorubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07340398 2026-01-21

TAYLOR

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting

HER2-positive Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡